A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. - Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; et al. (Neurobiology of disease, 2021)